Windlas Biotech Q1 FY27 Earnings Call — Analysis (NSE: WINDLAS)

Windlas Biotech delivered its highest ever quarterly revenue of ₹248 Cr (+18% YoY), driven by a 29% YoY surge in CDMO, while Trade Generics declined due to the codeine product discontinuation.

14 Aug 2026 · Analysis by Alpha Inflection

Result quality: stable — Steady quarter. Management sentiment: optimistic.

The take

Q1FY27 Revenue ₹248 Cr ( +18% YoY ) . New story: CDMO volume-led acceleration .

Results

Revenue ₹248 Cr +18% YoY; ex-ESOP EBITDA ₹34 Cr +26% YoY; PAT ₹18 Cr (₹25 Cr ex-ESOP, +37% YoY); CDMO ₹207 Cr +29% YoY; Exports ₹11 Cr +79% YoY; Trade Generics & Institutional ₹30 Cr impacted by codeine ban.

Financial highlights

Guidance

Plant 6 on track for commercialization by end-H1 FY27; no quantitative revenue or margin guidance provided.

What management committed to

• [Plant 6] will be commercialized by end of H1 FY27. — H1FY27
• With Plant 6, total revenue capacity is [₹1,100 Cr]. — ₹1,100 Cr
• Further debottlenecking could increase revenue capacity by [₹100-150 Cr] beyond the [₹1,100 Cr] initial estimate. — ₹100-150 Cr
• [Trade Generics & Institutional] revenue gap from [codeine-based product] discontinuation will be progressively bridged through new launches and replacements.

Key themes

CDMO momentum and capacity expansion offsetting Trade Generics drag

How the narrative shifted

• CDMO volume-led acceleration: Management frames the 29% CDMO growth as an outcome of sustained execution, customer expansion, and injectables contribution, while cautioning against extrapolating quarterly rates.
• Trade Generics codeine recovery: The codeine ban created a revenue hole; management is addressing it through portfolio diversification (liquids, more SKUs), geographic expansion, and sales force realignment, expressing confidence in a temporary hit.
• Incremental capacity discipline: Management strongly advocates for brownfield, incremental expansions over large greenfield plants to avoid overcapacity, protect margins, and maintain capital efficiency, while ensuring capacity is not a growth bottleneck.
• Export long-gestation pipeline: Exports are growing off a low base as earlier business development efforts convert, but it remains a higher gestation period business with ongoing registration and audit work; management positive but gives no timeline for scaling.
• API price volatility and cost-plus model: API prices remain volatile, but Windlas operates a transparent cost-plus partnership model where both input cost increases and decreases are passed through, muting P&L impact; focus remains on volume execution.
• IPM volume recovery as tailwind: Indian pharma market volume growth of 3.4% in Q1 is a welcome sign after a period of mild/negative volume growth; management hopes it is not a blip and stands to benefit indirectly as customers' brands grow.

Operational commentary

• Plant 6 mechanical completion done; customer audits underway; commercialization expected by end-H1 FY27, expanding oral solids capacity.
• CDMO growth driven by deeper customer engagement, new product launches, and injectables continuing to contribute to overall revenue.
• Trade Generics & Institutional revenue impacted by government-mandated discontinuation of codeine-based cough syrups; company bridging gap via new liquid products, more SKUs, pack-size variants, and geographic expansion.
• Exports vertical showing high growth (79% YoY) as long-gestation business development efforts convert; ongoing dossier registrations, plant audits, and new geography additions.
• Injectables capacity expansion back on track; basic infrastructure ready for additional lines if needed; timeline ~6-8 months for machinery addition.
• Capacity utilization at ~60-65%, peak ~65-70%; with Plant 6, total revenue potential initially ~₹1,100 Cr, with further debottlenecking possible (₹100-150 Cr more).
• Uttarakhand government imposed minimum wage hike with retrospective effect, adding to personnel costs; no extraordinary impact on margins.
• Management reiterated capital discipline philosophy: preference for incremental brownfield expansions over large greenfield to avoid overcapacity and margin dilution.

Analyst Q&A

• Q. What specific operational milestones should shareholders track for Plant 6 over the next 4-6 quarters?

  Mechanical completion done; validations and customer audits ongoing; commercialization by end-H1. Success signals will be revenue growth and cash flow generation, not just EBITDA.

• Q. Has the Trade Generics ex-codeine business grown YoY this quarter?

  Acknowledged momentum has taken a temporary hit; confident in bringing back momentum but avoided providing specific ex-codeine growth figure.

• Q. Which new large semi-regulated markets have been added for exports, and how are dossiers scaling in South Africa and Philippines?

  Declined to share details, citing competitive sensitivity.

• Q. Can you provide a broad breakup of volume vs price growth in CDMO this quarter?

  Stated that the majority of growth was volume-linked; API price impact is hard to isolate given the transparent cost-plus model, but no specific split provided.

View source

Research and educational content only. Not investment advice.